FGFR multi-TKI lucitanib has shown promising activity in overcoming that resistance; thus, there is potential for the combination use of CDK4/6 inhibitors with FGFR inhibitors in breast cancers with FGFR pathway alterations [42]. This evidence concerns the gene CDK4 and breast carcinoma.